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Background: The inflammatory myeloid cell activation is one of the hallmarks of experimental autoimmune
encephalomyelitis (EAE), yet the in vivo role of the inflammatory myeloid cell activation in EAE has not been clearly
resolved. It is well-known that IKK/NF-κB is a key signaling pathway that regulates inflammatory myeloid activation.
Methods: We investigated the in vivo role of inflammatory myeloid cell activation in myelin oligodendrocyte
glycoprotein (MOG) peptides-induced EAE using myeloid cell type-specific ikkβ gene conditional knockout-mice
(LysM-Cre/IkkβF/F).
Results: In our study, LysM-Cre/IkkβF/F mice had alleviated clinical signs of EAE corresponding to the decreased
spinal demyelination, microglial activation, and immune cell infiltration in the spinal cord, compared to the wild-
type mice (WT, IkkβF/F). Myeloid ikkβ gene deletion significantly reduced the percentage of CD4+/IFN-γ+ (Th1) and
CD4+/IL-17+ (Th17) cells but increased the percentages of CD4+/CD25+/Foxp3+ (Treg) cells in the spinal cord and
lymph nodes, corresponding to the altered mRNA expression of IFN-γ, IL-17, IL-23, and Foxp3 in the spinal cords of
LysM-Cre/IkkβF/F EAE mice. Also, the beneficial effect of myeloid IKKβ deletion in EAE corresponded to the decreased
permeability of the blood brain barrier (BBB).
Conclusions: Our findings strongly suggest that IKK/NF-kB-induced myeloid cell activation exacerbates EAE by
activating Th1 and Th17 responses and compromising the BBB. The development of NF-κB inhibitory agents with
high efficacy through specific targeting of IKKβ in myeloid cells might be of therapeutic potential in MS and other
autoimmune disorders.
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Multiple sclerosis (MS) is an autoimmune, demyelinat-
ing disease resulting from chronic inflammation in the
central nervous system (CNS). The pathological fea-
tures of MS are characterized by breakdown of the
blood-brain barrier (BBB), infiltration/recruitment of
peripheral immune cells consisting of lymphocytes and
macrophages, demyelination, axonal- and oligodendro-
cyte loss, and glial scar formation [1, 2, 14, 31, 42].
These pathological features of MS can be recapitulated
in the animal model for experimental autoimmune en-
cephalomyelitis (EAE). A series of studies have demon-
strated that myeloid cells in the spinal cord, namely
microglia and blood-derived macrophages, play pivotal
roles in the pathogenesis of MS and EAE. Studies thus
far indicate that the activation of these myeloid cells
contribute to MS and EAE lesion formation, as they
phagocytose myelin, leading to extensive myelin dam-
age and oligodendrocyte dysfunction [20]. In addition,
activated microglia and brain-infiltrating macrophages
in the demyelinated lesions produce inflammatory me-
diators including proinflammatory cytokines/chemo-
kines, nitric oxide, and reactive oxygen species, which
exert detrimental effects on MS and EAE by directly af-
fecting oligodendrocyte cell death and/or recruiting
autoreactive lymphocytes [20, 48, 57]. However, there
are also documents indicating that these activated
microglia/macrophages can be beneficial in the recov-
ery process after EAE [31, 47, 48]. For instance, alter-
natively activated microglia and macrophages facilitate
recovery from EAE by driving oligodendrocyte differ-
entiation during remyelination [44]. In addition, effi-
cient clearance of myelin debris and apoptotic cells in
the lesion site and secretion of neuroprotective media-
tors from activated microglia/macrophages may pro-
mote regeneration of the impaired axons [47]. Thus,
the in vivo role of macrophage/microglia activation in
EAE is still controversial. Furthermore, recent studies
revealed that microglia/macrophages display remark-
able plasticity in their activation phenotypes. They can
be activated as the “classically activated” M1 phenotype
that produces and releases proinflammatory mediators
[40] or the “alternatively activated” M2 phenotype that
promotes angiogenesis and matrix remodeling [55] de-
pending on their microenvironment. Therefore, the
specific function of microglia/macrophage activation in
the pathogenesis of EAE should be characterized ac-
cording to the activation phenotype of these cells.
The nuclear factor (NF)-κB signaling pathway plays a
central role in the expression of a wide variety of genes
controlling immune and inflammatory responses. Upon
stimulation, the canonical NF-κB pathway is activated by
the IκB kinase (IKK) complex, which is composed of two
catalytic subunits, IKKα and IKKβ [28, 41]. In microgliaand macrophages, IKK/NF-κB-dependent signaling path-
ways are critical for M1 phenotype-related proinflamma-
tory gene expression such as inducible nitric oxide
synthase (iNOS) and tumor necrosis factor (TNF)-α
[28, 41]. Due to its pivotal role in inflammatory myeloid
cell activation, we reasoned that by selectively inhibiting
the IKK/NF-κB signaling pathway in macrophages/
microglia, we would be able to address the in vivo func-
tion of inflammatory myeloid cell activation in EAE. For
the targeted analysis of NF-κB signaling, we used IKKβ-
conditional knockout mice, in which the ikkβ gene is
specifically deleted in myeloid cells, including the ma-
jority of microglia and macrophage populations [9, 18],
and investigated the in vivo role of the IKK/NF-κB-
dependent inflammatory myeloid cell activation during
the complex process of demyelination through the de-
velopment and progression of EAE. Our results showed
that IKK/NF-κB-dependent proinflammatory myeloid
cell activation exacerbates autoimmmune demyelin-
ation, Th17 cell infiltration, and BBB compromise dur-
ing EAE. These data suggest that pharmacological
targeting of the IKK/NF-κB signaling pathway, specific-
ally in myeloid cells, might have therapeutic benefits in
autoimmune demyelinating disorders including MS.Methods
Animals, genotyping, and ethic statements
Myeloid cell type-specific IKK-β-deficient (LysM-Cre/
IkkβF/F) mice were generated by crossing floxed-ikkβ
(IkkβF/F) mice and LysM-Cre knock-in mice express-
ing Cre under the control of the endogenous lyso-
zyme M promoter, as described previously [9, 10, 37].
The genetic background of both mice was C57BL/6.
PCR genotyping was performed using the primers 5′-
TGA CCC GGG AAT GAA TAG GA-3′ and 5′-GTC
TTC AAC CTC CCA AGC CTT-3′, which amplify
both the Ikkβ+ (220 bp) and IkkβF (310 bp) alleles.
LysM-Cre mice were genotyped by PCR using the pri-
mer pair NLS-Cre (5′-CCC AAG AAG AAG AGG AAG
GTG TCC-3′) and Cre8 (5′-CCC AGA AAT GCC AGA
TTA CG-3′) as previously described [9]. Adult (10–11
weeks after birth) female LysM-Cre/IkkβF/F and wild-type
(WT, IkkβF/F) mice were used.
Mice were housed at 23 ± 3 °C with a 12 h light–dark
cycle (light from 08:00 to 20:00) and food and water
were provided ad libitum. All experimental procedures
were reviewed and approved by the Institutional Animal
Care and Use Committee (IACUC) of Kyung Hee Univer-
sity and Seoul National University. Proper randomization
of laboratory animals and handling of data were per-
formed in a blinded manner in accordance with recent
recommendations from a NIH Workshop on preclinical
models of neurological diseases [30].
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Microglial cells were isolated from the lumbar spinal cord
of mice using CD11b microbeads (Miltenyil Biotec,
Germany). Briefly, spinal cords were dissected after perfu-
sion with PBS and single-cell suspensions were prepared
by using the neural tissue dissociation Kit (Miltenyil Bio-
tec) for 30 min at 37 °C. Pure single-cells were acquired by
passing the cells through a 40 μm strainer. Myelins were
removed by using myelin removal beads (Miltenyil Biotec)
for 15 min at 4 °C. Single cells were stained with anti-
CD11b antibody (Miltenyi Biotec) for 30 min at 4 °C. The
CD11b+ labeled single cells were separated by a magnetic
field through MS columns (Miltenyi Biotec). We con-
firmed that these cells were approximately 95 % pure, as
assessed by CD11b+ and CD45+ cytometry analysis. Iso-
lated microglia cells were used in real-time reverse tran-
scription (RT)-polymerase chain reaction (PCR) analysis to
investigate the level of IKKβ deletion in spinal microglia,
as previously described [26], using the primer summarized
in Additional file 1.
Isolation of peritoneal macrophages and
lipopolysaccharide-stimulation
Two ml of 2 % thioglycollate (BD Bioscience) was intra-
peritoneally administered to adult mice (n = 5 per
group), to collect peritoneal macrophages. After 3–4
days, the peritoneal macrophages were harvested and
isolated. The macrophages were distributed in Eagle’s
minimal essential medium (EMEM) supplemented with
10 % heat-inactivated fetal bovine serum (FBS), seeded
onto 24 plates (2.5 × 105 cells/well), and incubated for 3 h
at 37 °C in an atmosphere of 5 % CO2. After 4 h, non-
adherent cells were removed by washing with Hanks bal-
anced salt solution (HBSS) and the adherent cells (macro-
phages) were equilibrated with DMEM containing 10 %
FBS before incubation with lipopolysaccharide (0111:B4;
100 ng/ml; Sigma-Aldrich) for 6 h. The macrophages were
collected to analyze the mRNA levels of cytokines, includ-
ing TNF-α, IL-1β, IL-6, and iNOS by real time RT-PCR
using the primers summarized in Additional file 1.
M1/M2 polarization of peritoneal macrophages
To analyze M1/M2 polarization of macrophage cells,
macrophages equilibrated with DMEM were treated
with lipopolysaccharide (0127:B8; 50 ng/ml; Sigma-Aldrich)
for 4 h or IL-4 (0.1 ng/ml; R&D system) for 24 h. These
macrophages were incubated with FITC anti-mouse
F4/80 (F480, eBioscience), PE anti-mouse CD80 (B7-1;
eBioscience), APC anti-mouse CD86 (B7-2, eBioscience),
and APC anti-mouse CD206 (MMR, Biolegend) (Additional
file 2) for 30 min at 4 °C. After washing twice with 2 % FBS
in PBS, macrophages were used for flow cytometry analysis.
Data were collected on a FACS Calibur flow cytometer (BD
Biosciences) and analyzed using Cell Quest Pro software(BD Biosciences). Alteration in protein expression of M1
(iNOS) and M2 marker (arginine-1) was analyzed using
protocol as described in 2.11. Western blot analysis.Preparation of spinal cord for real time RT-PCR and West-
ern blot analyses
At the peak day of neurological impairment (15–18 days
post-immunization), the mice used for real-time RT-
PCR and Western blot analysis (n = 5 per group) were
anesthetized. Each lumbar spinal cord was removed and
deep-frozen.Real-time RT-PCR
Real-time RT-PCR was performed using SYBR Green PCR
Master Mix (ABI, Warrington, UK) as described previ-
ously [9, 25, 34]. Reactions were performed in duplicate in
a total volume of 10 μl containing 10 pM primer, 4 μl
cDNA, and 5 μl SYBR Green PCR Master Mix. The
mRNA levels of each target gene were normalized to that
of GAPDH mRNA. Fold-induction was calculated using
the 2−ΔΔCT method, as previously described [39]. All real-
time RT-PCR experiments were performed at least thrice
and the mean ± SEM values are presented unless other-
wise noted. The PCR primer sequences used in this study
are listed in Additional file 1.Histopathological analysis of spinal cord
Histopathological analysis of the spinal cord was per-
formed as described previously [9, 23, 33, 34]. Detailed
methods can be found in the Additional file 3.EAE induction and clinical evaluation
EAE induction and clinical evaluation was performed as
previously described [32–34]. Detailed methods can be
found in the Additional file 3.Quantification of demyelination and cell recruitment/
infiltration
Methods for quantification of demyelination and cell re-
cruitment/infiltration are presented in Additional file 3.Immunohistochemical analysis
Immunohistochemical analysis was performed as pre-
viously described [9, 25, 33, 34], using antibodies in
Additional file 2. Detailed methods can be found in the
Additional file 3.Western blot analysis
Western blot analysis was performed as previously described
[25, 26, 33, 34], using antibodies in Additional file 2. Detailed
methods can be found in the Additional file 3.
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At the peak day of neurological impairment, five mice in
each group were anesthetized. Their spleen and lymph
nodes were carefully removed without fat, connective
tissue, or fluid. They were weighted using a microbal-
ance (OHAUS, Parsippany, U.S.A.).
Flow cytometry
For flow cytometry analysis, 5 mice in each group were
anesthetized. The lumbar spinal cord and lymph nodes
were carefully dissected and dissociated at the time of the
peak clinical score as previously described [23, 33, 34]. A
single-cell suspension was prepared and fixed with 2 %
paraformaldehyde for surface cell analysis. Cells were then
washed with 2 % FBS in PBS, incubated with mouse anti-
rat CD32 (BD Biosciences, San Jose, CA, USA) for 10 min
to block the Fc receptor and washed twice with 2 % FBS
in PBS. For surface cell analysis, cells were incubated with
APC anti-mouse CD11b (OX-42; Biolegend, San Diego,
CA, USA), PE anti-mouse CD45 (OX-1; Biolegend), APC
anti-mouse CD4 (OX-35, BD Biosciences), and PE anti-
mouse CD8a (OX-8, BD Biosciences) for 30 min at 4 °C.
Microglia and macrophages were identified based on their
relative CD45 expression levels [54]. Briefly, after acquir-
ing unstained and single color control samples to calculate
compensation matrix, we acquired 1 × 104 events within
the combined gate based on physical parameters [forward
scatter (FSC) and side scatter (SSC)]. CD11b+/CD45+(low)
cells and CD11b+/CD45+(high) cells were gated as resident
microglia and macrophages, respectively [54]. For intracel-
lular cell analysis, cells were restimulated with phorbol-
12-myristate-13-acetate and ionomycin and Golgistop in
RPMI media. After 5 h, cells were stained with PerCP-Cy
5.5 anti-mouse CD4 (RM4-5; BD Biosciences), FITC anti-
mouse IFN-γ (XMG1.2; BD Biosciences), PE anti-mouse
IL-17A (TC11-18H10; BD Biosciences), PE anti-mouse
IL-4 (11B11; BD Biosciences), PE anti-mouse CD25
(PC61.5; FJK-16 s; eBioscience), and APC anti-mouse/rat
Foxp3 (FJK-16 s; eBioscience) (Additional file 2) for
30 min at 4 °C. The cells were washed twice with 2 % FBS
in PBS and used for flow cytometry. To identify CD4+ T
cell populations, we first gated on cells (1 × 104) based on
FSC and SSC properties. CD4+ T cells were used to
analyze populations of Th1, Th2, Th17, and Treg cells on
CD4. Three-color staining was performed for one cell for
simultaneous analysis. Intracellular cytokine results were
indicated as percentages within the CD4+ population.
Data were collected on a FACS Calibur flow cytometer
(BD Biosciences) and analyzed using Cell Quest Pro soft-
ware (BD Biosciences).
T cell culture and proliferation
Methods for T cell culture and proliferation are pre-
sented in Additional file 3.Co-culture of microglia with T cells
Primary mixed glia was isolated from brains of postnatal
1–3 day WT or LysM-Cre/IkkβF/F mice. After removing
meninges of brain, single-cells were cultured in DMEM
containing 10 mM HEPES, 10 % FBS, 2 mM L-glutam-
ine, and antibiotic/antimycotic in 75 cm2 flasks at 37 °C
with 5 % CO2. Culture medium was changed every 2–3
days and glia cultured for 14 days. Detached microglial cells
were incubated for 30 min. Non-adherent cells were
removed. These cells were approximately 95 % pure based
on CD11b+ flow cytometry analysis. At 15 days after EAE
induction, 95 % pure CD4+ T cells were harvested from
lymph node cells of WT and LysM-Cre/IkkβF/F mice by
anti-mouse CD4 magnetic beads (Miltenyil Biotec). CD4+
T cells (2 × 106 cells/ml) were re-stimulated with MOG35–55
peptide (25 μg/ml) in the presence IL-2 and IL-12 (20 ng/
ml, R&D Systems). After 7 days of culturing, surviving
MOG35–55 peptide-specific T cells were co-cultured with
microglia in DMEM containing 10 % FBS and MOG35–55
peptide (25 μg/ml). T cells were added to the microglia at
an estimated ratio of 1:2 (0.5 × 105 T cells: 1 × 105 micro-
glia). After 24 h, cells were harvested and subjected to Tcell
differentiation analysis using flow cytometry as described
above.Evaluation of BBB disruption
The level of BBB disruption was detected by quantita-
tive measurement for Evans blue content at the peak
day of neurological impairment after immunization, as
previously described [63]. Briefly, sterilized 2 % Evans blue
solution was intravenously injected at a dose of 4.0 ml/kg
per mouse (n = 5 per group). Thirty minutes after injec-
tion, the mouse was perfused with saline to remove the
Evans blue dye in the vascular system. The brain and lum-
bar spinal cord were immediately removed, and images
were captured. The brain and lumbar lesion of the spinal
cord were homogenized with 2.5 ml PBS and mixed with
2.5 ml 60 % trichloroacetic acid to precipitate protein. The
samples were centrifuged for 30 min at 1,000 g, and the
supernatants were measured at 610 nm for the absorbance
of Evans blue by using an enzyme-linked immunosorbent
assay reader (Soft Max Pro-5; Molecular devices, CA,
USA). The Evans blue content was expressed as micro-
grams per gram of brain and lumbar spinal cord. To histo-
logically and immunohistochemically investigate BBB
permeability, 2 h after Evans blue solution injection to
EAE mice, spinal cords were harvested from each group
(n = 5 per group) and fixed with 4 % paraformaldehyde
solution. Cryo-sections in 30 μm thickness were prepared
and used to evaluate extravasation of Evans Blue dye using
confocal microscopy. Immunofluorescent staining was
performed as described above (Immunohistochemical
analysis).
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Induction of transferred EAE was performed with pub-
lished method [6, 43] with slight modifications. Briefly,
T cells were isolated from lymph nodes of WT or LysM-
Cre/IkkβF/F donor 15–18 days after induction of active
EAE and re-stimulated with MOG35–55 peptide (25 μg/
ml) in the presence IL-2 and IL-12 (20 ng/ml, R&D Sys-
tems, Minneapolis, U.S.A.) in RPMI 1640 medium con-
taining 10 % FBS and 1 % penicillin/streptomycin for
3 days. Purified T cells (1 × 107) were transferred i.v. into
sub-lethally irradiated WT or LysM-Cre/IkkβF/F recipient
mice. Disease development was daily monitored.
Statistical analyses
Statistical analysis was performed using the SPSS 21.0
package (SPSS Inc, Chicago, USA) for Windows. Neuro-
logical scores obtained by EAE induction were analyzed
using two-way analysis of variance (ANOVA) with re-
peated measures with one within-subjects factor (time)
and two between-subject factors (WT and LysM-Cre/
IkkβF/F mice). The data from immunohistochemistry,
Western blot, and PCR analysis were analyzed using
one-way ANOVA with Tukey post hoc test for compari-
son of multiple groups. The data were presented as
mean ± SEM. P values of less than 0.05 were accepted as
statistically significant.
Results
Myeloid-specific ikkβ gene deletion regulates M1/M2
polarization of macrophages
To investigate the in vivo function of proinflammatory
macrophage/microglia activation in EAE, we used LysM-
Cre/IkkβF/F mice. We have previously demonstrated that
the ikkβ gene was deleted specifically in peripheral mac-
rophages and in brain microglia isolated from LysM-Cre/
IkkβF/F mice [9]. To study the effects of ikkβ deletion in
EAE when demyelinating lesions are most prominent at
the spinal cord level, we first confirmed the cell type-
specific ikkβ gene deletion in spinal cord myeloid cells
isolated from LysM-Cre/IkkβF/F mice. In CD11b+ spinal
cord myeloid cells isolated from the LysM-Cre/IkkβF/F
mice, expression of the IKKβ transcript was reduced by
70 % compared to WT mice (Fig. 1a). To test the effects
of ikkβ deletion on the macrophage activation pheno-
type, we stimulated peritoneal macrophages derived
from WT and LysM-Cre/IkkβF/F mice with lipopolysac-
charide, and then measured the gene expressions involved
in inflammatory (M1) (TNF-α, IL-1β, IL-6, and iNOS) as
well as alternative (M2) [IL-10 and transforming growth
factor (TGF)-β] macrophage activation. Upon lipopolysac-
charide stimulation for 6 h, TNF-α, IL- β, IL-6, and iNOS
gene expressions were upregulated by 100.5 ± 0.5, 400 ±
0.7, 23.5 ± 0.4, and 19.7 ± 0.3 in the WT macrophages,
respectively, compared to normal control (11.15 ± 0.65,34.44 ± 15.21, 1.32 ± 0.59, and 1.11 ± 0.51) (Fig. 1b). In
contrast, the induction levels of these M1 markers were
reduced by more than 50 % in LysM-Cre/IkkβF/F macro-
phages (Fig. 1b). To the contrary, lipopolysaccharide
stimulation inhibited IL-10 and TGF-β expression by 18.5 ±
1.3 % and 31.4 ± 2.4 %, respectively, in WT macrophages,
compared to normal control (Fig. 1b). However, the inhib-
ition of these M2 markers was significantly ameliorated in
LysM-Cre/IkkβF/F macrophages. Gene expression levels of all
inflammatory mediators in quiescent state (0 h) between
WT and LysM-Cre/IkkβF/F macrophages were comparable.
In addition, we compared the populations of M1 (CD80- or
CD86-positive) and M2 (CD206-positive) macrophages
before and after lipopolysaccharide or IL-4 stimulation to
understand M1/M2 polarization by flow cytometry analysis.
As expected, the percentages of CD80- (3.5 ± 0.8 %;
572.0 ± 125.1 cells) and CD86-positive cells (2.9 ±
1.9 %; 221.0 ± 114.2 cells) in WT macrophages were
significantly increased to 64.5 ± 8.5 % (4,917 ± 253.4
cells) and 43.9 ± 5.3 % (3,337 ± 521.3 cells), respectively,
after lipopolysaccharide stimulation (Fig. 1c), while the
percentage of CD206-positive cells (3.2 ± 1.3 %; 308 ±
143.4 cells) in LysM-Cre/IkkβF/F macrophages was sig-
nificantly increased to 84.3 ± 4.4 % (8,312 ± 281.3 cells)
after IL-4 stimulation (Fig. 1d). These results were in
agreement with the alteration in protein expression
level of M1 (iNOS) and M2 marker (Arginine-1) after
lipopolysaccharide stimulation in WT or LysM-Cre/
IkkβF/F macrophages (Fig. 1e). As NF-κB signaling in
Schwann cells is implicated in peripheral myelination
[49], we examined whether ikkβ deletion in myeloid
cells affected myelination in the spinal cord during de-
velopment. Toluidine blue staining of lumbar spinal
cord semi-thin sections displayed a similar pattern of
myelination in the white matter of WT and LysM-Cre/
IkkβF/F mice (Fig. 1f-i). Likewise, the protein (Fig. 1j
and k) and mRNA expression (Fig. 1l and m) of the
myelin basic protein (MBP) as a marker for the degree
of myelination in the spinal cord tissue were compar-
able (Fig. 1j-m).
Myeloid-specific ikkβ gene deletion alleviates neurological
impairment and spinal demyelination during EAE
We then induced EAE in WT and LysM-Cre/IkkβF/F
mice by immunizing MOG35–55 peptide and monitored
the clinical symptoms of EAE. MOG35–55 peptide
immunization induced EAE-related symptoms in all
the immunized WT and LysM-Cre/IkkβF/F mice (7 out
7 mice) (Fig. 2a, b, and Table 1). In the WT mice, the
first clinical signs appeared around day 7–8 (7.6 ± 0.7)
and peaked around day 15 after immunization. How-
ever, LysM-Cre/IkkβF/F mice had a remarkably delayed
mean day of onset (10.2 ± 0.5) and ameliorated clinical
symptoms (mean day of onset, maximal clinical score,
Fig. 1 (See legend on next page.)
Lee et al. Molecular Neurodegeneration  (2016) 11:54 Page 6 of 21
(See figure on previous page.)
Fig. 1 Myeloid cells of LysM-Cre/IkkβF/F mice are relatively refractory to M1-like proinflammatory activation. a CD11b+ cells were isolated from the
lumbar spinal cord of adult WT and LysM-Cre/IkkβF/F mice using CD11b microbeads. Genomic DNA from CD11b+ cells of each group was analyzed
by real-time RT-PCR to determine the rate of ikkβ deletion. b Macrophages obtained from normal WT and LysM-Cre/IkkβF/F mice were stimulated
for 6 h with lipopolysaccharide. Macrophages were isolated and analyzed to evaluate the degree of activation of TNF-α, IL-1β, IL-6, iNOS, IL-10,
and TGF-β with real-time RT-PCR. The levels of gene expressions were compared to normal control. c-e Macrophages derived from WT and LysM-
Cre/IkkβF/F mice were treated with lipopolysaccharide or IL-4, incubated with PE anti-mouse CD80 (c), APC anti-mouse CD86 (c), and APC anti-
mouse CD206 (d), and used for flow cytometry analysis (c and d). Alteration in protein expression of M1 (iNOS) and M2 marker (Arginine-1) was
analyzed by Western blot analysis (e). f-i Semi-thin sections from the lumbar spinal cord of adult WT (F and H) and LysM-Cre/IkkβF/F mice (g and i)
were stained with toluidine blue. Panels h and i display high magnification micrographs of sections in (panels f and g) marked with squares,
respectively. Bars = 100 μm. j-m Spinal cord lysate obtained from adult WT and LysM-Cre/IkkβF/F mice was analyzed for the expression of MBP by
immunoblotting (j) and were quantified (k). The same preparation was analyzed for mRNA expression of MBP by real-time RT-PCR (l) and was
quantified (m). Data are representative of 3 independent experiments with similar results. (ANOVA test; **p < 0.01 and *p < 0.05 versus WT mice;
#p < 0.05 and ##p < 0.01 versus normal control mice)
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Table 1). Mean body weight decreased negatively in
correlation with the clinical score in the WT mice but
was significantly increased in the LysM-Cre/IkkβF/F
mice (Fig. 2b). Sections of lumbar spinal cord prepared
from WT and LysM-Cre/IkkβF/F mice at the peak clin-
ical signs (around day 15–18 after immunization) were
stained with luxol fast blue (LFB) to examine whether
the severity of clinical signs is correlated with the level
of spinal demyelination. In the EAE-induced WT mice,
LFB-negative areas representing demyelinated lesions
appeared in the ventral spinal cords. However, the level
of demyelination was markedly reduced in the LysM-
Cre/IkkβF/F mice (Fig. 2c-f and k). In accordance with
the LFB data, demyelinated lesions were also detected
by MBP immunostaining in the WT spinal cord after
EAE induction. In LysM-Cre/IkkβF/F spinal cord, how-
ever, MBP-negative lesion areas were not as obvious as
in the WT spinal cord (Fig. 2g-j and l). In line with the
immunohistochemical data, MBP protein expression
was reduced by 37.3 % in EAE-induced WT spinal cord
tissue compared to the sham-control, whereas it was
reduced by only 11.3 % in the LysM-Cre/IkkβF/F mice
(Fig. 2m and n).
Myeloid-specific ikkβ gene deletion inhibits the
recruitment/infiltration of microglia and macrophages in
spinal cord lesion during EAE
We then assessed whether the reduced clinical signs and
demyelination in LysM-Cre/IkkβF/F mice was associated
with the level of activation and recruitment of immune
cells into demyelinated lesions by H&E staining. Consist-
ent with the severity level in clinical symptoms and de-
myelination, immune cell infiltration on the peak day
markedly increased in the white matter of the spinal cords
of EAE-induced WT mice compared to sham-control
mice (Fig. 3a-d and m). Inflammatory cells were detected
adjacent to the subarachnoid space, within the paren-
chyma in perivascular lesions, and in the spinal cord ofWT mice. However, their distribution was significantly re-
stricted in the spinal cord of LysM-Cre/IkkβF/F mice
(Fig. 3a-d and m). Similarly, the EAE-induced microglia
activation and macrophage infiltration measured by ion-
ized calcium-binding adapter molecule-1 (Iba-1) and
CD68-immunoreactivity, respectively, were substantially
reduced in the spinal cords of LysM-Cre/IkkβF/F mice
(Fig. 3e-l and n). In agreement with the histological data,
mRNA expression of CD11b (a marker of myeloid cells)
was also up-regulated in the spinal cord of WT mice by
EAE induction, while the induction level was reduced by
more than 80 % in the spinal cords of LysM-Cre/IkkβF/F
mice (Fig. 3o). Since there are limitations with differen-
tiating macrophages and microglia based on immuno-
histochemistry, we further characterized microglia vs.
macrophage populations by flow cytometry. Upon
immunization, the percentage of CD11b+/CD45+(low)
cells (R3 rectangle in Fig. 3p) representing brain resi-
dent microglia [9, 23, 33, 34] was increased to 2.13 ±
0.43 % in the WT spinal cords, whereas it was increased
to 1.12 ± 0.20 % in LysM-Cre/IkkβF/F spinal cords
(Fig. 3p and q). The percentage of CD11b+/CD45+(high)
cells (R2 rectangle in Fig. 3p) representing macrophages
was also increased to 6.77 ± 1.10 % in the WT spinal
cords, whereas it was increased to only 4.44 ± 0.53 % in
LysM-Cre/IkkβF/F spinal cords (Fig. 3p and q). To con-
firm the effect of myeloid ikkβ deletion in curtailing the
M1-like proinflammatory macrophage/microglia activa-
tion in the spinal cord in vivo, we compared the expres-
sion levels of M1 marker genes (IL-1β, TNF-α, and
iNOS) between the lumbar spinal cords of WT and
LysM-Cre/IkkβF/F mice 15–18 days after immunization
(Fig. 3r-t). In the spinal cord of WT mice, upon EAE in-
duction, the mRNA expression of IL-1β, TNF-α, and iNOS
were increased by 22.3 ± 0.3, 7.1 ± 1.1, and 2.3 ± 2.1, re-
spectively. The EAE-induced IL-1β expression was almost
completely blocked in the LysM-Cre/IkkβF/F mice (Fig. 3r).
TNF-α and iNOS expressions were also substantially com-
promised in the LysM-Cre/IkkβF/F mice (Fig. 3s and t).
Fig. 2 Myeloid-specific ikkβ gene deletion alleviates neurological impairment and demyelination in the spinal cord during EAE. a and b The
clinical signs for all WT and LysM-Cre/IkkβF/F EAE mice were scored (a) and weighed (b) daily for 30 days. c-l Spinal cord sections were obtained
from WT (e, i, k, and l) and LysM-Cre/IkkβF/F mice (f, j, k, and l) at 15–18 days after immunization, stained with luxol fast blue (c-f) or
immunostained with MBP antibody (g-j), and analyzed to measure the degree of demyelination by immunization (k and l). Bars = 10 μm. m and
n Spinal cord lysate obtained from WT and LysM-Cre/IkkβF/F mice at 15–18 days after immunization were analyzed for the expression of MBP by
immunoblotting (m) and were quantified (n). Data are representative of 3 independent experiments with similar results. Data are expressed as
mean clinical scores ± SEM. (ANOVA test; *p < 0.05 and **p < 0.01 versus WT EAE mice; #p < 0.05 and ##p < 0.01 versus normal control mice)
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lymphatic organs and inhibits the differentiation/
proliferation of CD4+ T cells during EAE
Since hypertrophy of spleen and lymph nodes are ob-
served in EAE mice [46], we measured weight to comparetheir sizes at 15–18 days after immunization. As expected,
their weights were increased by immunization. The in-
crease in weights of spleen (0.38 ± 0.01 g) and lymph
nodes (0.10 ± 0.01 g) of LysM-Cre/IkkβF/F mice were sig-
nificantly lower than that of WT mice (0.68 ± 0.04 g in
Table 1 Myeloid-specific ikkβ gene deletion ameliorates a subsequent encephalogenic challenge
Group Incidence (%) Mean day of onset (± SEM) Maximal clinical score (± SEM) Sun of clinical score (± SEM) Mortality (%)
PBS Wild type 3/3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0
LysM-Cre/IkkβF/F 3/3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0
MOG Wild type 7/7 7.6 ± 0.7 3.4 ± 0.2# 64.1 ± 1.7# 0
LysM-Cre/IkkβF/F 7/7 10.2 ± 0.5 2.6 ± 0.2* 17.3 ± 3.0* 0
ANOVA test; *p < 0.05 versus WT EAE mice; #p < 0.05 versus normal control mice
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Activation and recruitment of auto-reactive T cells are
critical initiators and mediators of EAE pathogenesis
[22]. To investigate the mechanisms underlying the
ameliorated EAE pathogenesis in the LysM-Cre/IkkβF/F
mice, we examined the extent of T cells infiltration into
the spinal cord of WT and LysM-Cre/IkkβF/F mice after
EAE induction. The mRNA expression of CD3, as a
marker for T cells, was increased by 40-fold in the
spinal cord of WT mice on days 15–18 of EAE, which
was almost completely blocked in LysM-Cre/IkkβF/F
mice (Fig. 4c). Characterization of the T cell subtypes
by flow cytometry showed that the percentage of CD4+
T cells was markedly increased after EAE induction in
the spinal cord (14.47 ± 1.21 %; Table 2 and Additional
file 4a) and lymph nodes (27.77 ± 2.33 %; Table 2 and
Additional file 4b) of WT mice. However, the increase
in CD4+ Th cells was significantly diminished in LysM-
Cre/IkkβF/F EAE mice both in the spinal cord (8.18 ±
0.53 %; Table 2 and Additional file 4a) and lymph nodes
(19.96 ± 2.96 %; Table 2 and Additional file 4b). The
percentage of cytotoxic CD8+ T cells was not signifi-
cantly affected by immunization or myeloid IKKβ dele-
tion (Table 2 and Additional file 4a and b). In naïve
mice, the percentages of CD4+ T cells and CD8+ T cells
in the spinal cords (Table 2 and Additional file 4a) and
lymph nodes (Table 2 and Additional file 4b) were
comparable in WT and LysM-Cre/IkkβF/F mice.
Myeloid-specific ikkβ gene deletion decreases the
percentages of CD4+ T, Th1, and Th17 cells but increases
the percentage of Treg cells during EAE
Since naïve CD4 T cells may differentiate into Th1, Th2,
Th17, and regulatory T (Treg) cells during T cell receptor
(TCR) activation in a particular cytokine milieu involved in
autoimmunity, we characterized each subtype of CD4+ T
cells in the EAE-induced spinal cord. It is well-known that
MS/EAE is mediated by encephalitogenic Th1 and Th17
cells that produce proinflammatory cytokines such as IFN-
γ and IL-17, respectively [12, 59]. Thus, we investigated the
effects of myeloid IKKβ deletion on the infiltration/activa-
tion of CD4+/IFN-γ+ (Th1) and CD4+/IL-17+ T (Th17)
cells in the spinal cords and lymph nodes. In the EAE-
induced mice, the CD4+/IFN-γ+ Th1 population increased
to 11.33 ± 0.69 % and 9.40 ± 1.98 % in the spinal cord(Table 2 and Additional file 4a) and lymph node (Table 2
and Additional file 4b), respectively. Similarly, CD4+/IL-17+
T cell populations in the spinal cord and lymph node in-
creased to 14.35 ± 1.21 % (Table 2 and Additional file 4a)
and 14.76 ± 2.64 % (Table 2 and Additional file 4b), respect-
ively. However, in LysM-Cre/IkkβF/F mice, Th1 and Th17
cells increased to only 6.34 ± 0.22 % and 5.43 ± 0.63 %, re-
spectively, in the spinal cord (Table 2 and Additional file
4a) and to 4.59 ± 0.72 % and 4.13 ± 0.66 %, respectively, in
the lymph nodes (Table 2 and Additional file 4b). Addition-
ally, mRNA induction of IFN-γ, IL-23 (an interleukin that
induces differentiation of naïve Th cells to Th17 cells), and
IL-17 in the EAE-induced spinal cord was markedly
reduced by myeloid IKKβ deletion (Fig. 4d-f). The per-
centage of CD4+/IL-4+ Th2 cells in the spinal cords
(Table 2 and Additional file 4a) or lymph nodes (Table 2
and Additional file 4b) was not significantly altered in WT
and LysM-Cre/IkkβF/F mice upon EAE induction. Like-
wise, mRNA expressions of IL-4 (a cytokine that induces
the differentiation of naïve Th cells to Th2 cells) and IL-5
(an interleukin produced by Th2 cells) were not signifi-
cantly affected by immunization or myeloid IKKβ deletion
(Fig. 4g and h). Interestingly, the number of CD4+/Foxp3+
and CD4+/CD25+/Foxp3+ Treg cells that maintain toler-
ance to self-antigens and suppress autoimmune responses
increased in the spinal cord of EAE-induced mice com-
pared to normal control mice (0.46 ± 0.06 % vs. 1.55 ±
0.15 %) (Table 2 and Additional file 4a). Notably, this in-
crease was further potentiated by myeloid IKKβ deletion
(0.47 ± 0.10 % vs. 4.05 ± 0.80 %), which corresponded with
mRNA expression of Foxp3 (a “master gene” for control-
ling the development and function of Treg cells) in the
spinal cord (Fig. 4i). Although the Treg cell populations in
the lymph node were reduced in EAE-induced mice com-
pared to the sham-control, there were still more Treg cells
in the LysM-Cre/IkkβF/F mice compared to the WT mice
(Table 2 and Additional file 4b).
Myeloid-specific ikkβ gene deletion inhibits the activity of
co-stimulatory factors in macrophages and regulates the
differentiation/proliferation of T cells by co-culture with
microglia
We next investigated the direct effect of myeloid cell
specific IKKβ deletion on antigen-specific T cell prolifer-
ation in EAE. When spleen mononuclear cells from WT
Fig. 3 (See legend on next page.)
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Fig. 3 Myeloid-specific ikkβ gene deletion inhibits the recruitment/infiltration of residential microglia and of peripheral macrophages in spinal cord
lesion during EAE. a-n Spinal cord sections were obtained from WT and LysM-Cre/IkkβF/F mice (n = 5) at 15–18 days after immunization, stained with
H&E dye (a-d), and immunostained with anti-Iba-1 (e-h) and anti-CD68 antibodies (i-l) to investigate the degree of cellular recruitment/infiltration.
Representative photographs show ventrolateral white matter of the lumbar spinal cord (a-l). The degree of recruitment/infiltration was quantified and
the data are expressed as mean score ± SEM (m and n). Bars = 100 μm. o Spinal cords from each group (n = 5) at 15–18 days after immunization were
analyzed with real-time RT-PCR. Data are expressed as mean fold induction ± SEM. p and q Spinal cords were dissected from each group (n = 5) at 1
5–18 days after immunization to investigate the degree of recruitment/infiltration of macrophages with flow cytometry. Tissues were dissociated, and
cells were incubated with APC-conjugated anti-CD11b and PE-conjugated anti-CD45 antibodies. CD11b+ cells were divided into CD11b+/CD45+(high)
cells (R2; macrophage) and CD11b+/CD45+(low) cells (R3; microglia) populations based on CD45 expression levels (p), and the percentages of each
population are denoted in the graph (q). Mean ± SEM values from 3 independent experiments are shown in the graph. r-t Total RNA was isolated from
the lumbar spinal cord of each group (n = 3) at day 15–18 post-immunization to measure the level of the mRNA expression of IL-1β (r), TNF-α (s), and
iNOS (t) with real-time RT-PCR. The mRNA level of each gene is presented as the fold induction ± SEM compared with the levels measured in the
normal control mice. (ANOVA test; *p < 0.05 and **p < 0.01 versus WT EAE mice; #p < 0.05 and ##p < 0.01 versus normal control mice)
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tide, significant splenocyte proliferation, a measure of
autoreactive T cell proliferation, was detected in WT
mice, but was markedly diminished in splenocytes pre-
pared from LysM-Cre/IkkβF/F mice (Fig. 5a and b). The
proteolipid (PLP) peptide failed to induce T cell prolifer-
ation in both WT and LysM-Cre/IkkβF/F spleen cells, in-
dicating MOG35–55 peptide-specific autoreactive T cell
proliferation (Fig. 5a and b). T cell activations are regu-
lated by co-stimulatory signals from antigen presenting
cells [17]. To test whether the diminished auto-reactive
T cell proliferation observed in LysM-Cre/IkkβF/F spleno-
cyte culture was due to reduced co-stimulatory signals
from the IKKβ-deleted myeloid cells, we tested the expres-
sion of co-stimulatory molecules on WT and LysM-Cre/
IkkβF/F macrophages. Upon lipopolysaccharide stimula-
tion, the CD40, CD80, and CD86 transcripts were induced
in WT macrophages by 35.7 ± 2.5, 32.9 ± 6.1, and 8.8 ±
0.9, respectively (Fig. 5c-e). However, lipopolysaccharide-
stimulated costimulatory molecule expression was signifi-
cantly reduced in macrophages from LysM-Cre/IkkβF/F
mice (Fig. 5c-e), which might contribute to the reduced
autoreactive T cell responses in the LysM-Cre/IkkβF/F
mice. Nevertheless, it is hard to understand whether these
were cause or consequence phenomenon and how dele-
tion of IKKβ in myeloid cells might have induced Th1,
Th17, and Treg cells. Thus, we performed co-culture
experiments of microglia and CD4+ T cells derived from
WT and LysM-Cre/IkkβF/F mice. The percentages (6.93 ±
0.32 % and 6.72 ± 0.92 %) of CD4+/IFN-γ+ and CD4+/IL-
17+ cells in the co-culture group of LysM-Cre/IkkβF/F
microglia and WT CD4+ T cells were lower than that in
the co-culture group of WT microglia and WT CD4+ T
cells (14.44 ± 0.94 % and 9.00 ± 0.40 %), while the per-
centage (3.86 ± 0.67 %) of CD4+/CD25+/Foxp3+ cells in
the co-culture group of LysM-Cre/IkkβF/F microglia
and WT CD4+ T cells was higher than that in the co-
culture group of WT microglia and WT CD4+ T cells
(1.52 ± 0.33 %) (Fig. 5f ). The percentages (3.69 ± 1.50 %and 1.35 ± 0.43 %) of CD4+/IFN-γ+ and CD4+/IL-17+
cells in the co-culture group of LysM-Cre/IkkβF/F
microglia and LysM-Cre/IkkβF/F CD4+ T cells were
lower than that in the co-culture group of LysM-Cre/
IkkβF/F microglia and WT CD4+ T cells. And the per-
centage (7.03 ± 0.57 %) of CD4+/CD25+/Foxp3+ cells in
the co-culture group of LysM-Cre/IkkβF/F microglia
and LysM-Cre/IkkβF/F CD4+ T cells was higher than
that in the co-culture group of LysM-Cre/IkkβF/F
microglia and WT CD4+ T cells (Fig. 5f ).
Myeloid-specific ikkβ gene deletion inhibits BBB
permeability with during EAE
Besides auto-reactive T cell activation, blood brain barrier
(BBB) compromise is a pathological hallmark of EAE
pathogenesis [1, 2, 14, 31, 42]. Consequently, we charac-
terized the EAE-induced BBB disruption in WT and
LysM-Cre/IkkβF/F mice by Evans blue leakage on the peak
day of EAE clinical signs. The macroscopic images of the
brain and spinal cord showed that the degree of Evans
blue leakage was significantly reduced in LysM-Cre/IkkβF/F
mice (Fig. 6a). For quantification, the Evans blue content
was increased up to 16.6 ± 0.5 mg/g in the brain and to
1.9 ± 0.1 mg/g in the lumbar spinal cord of the WT EAE
mice compared with the baseline level of the sham-
control mice, whereas the Evans blue contents in the
LysM-Cre/IkkβF/F mice were only 10.1 ± 0.1 mg/g in the
brain and 1.3 ± 0.1 mg/g in the lumbar spinal cord
(Fig. 6b). In agreement with these results, confocal micro-
scopic images (Fig. 6c-f) and their quantified graph
(Fig. 6g) showed that the intensity of Evans blue dye was
increased by 134.56 ± 0.36 pixels in the white matter of
lumbar spinal cord of the WT EAE mice compared to the
baseline level of the sham-control mice 33.45 ± 8.22 pixels),
whereas the intensity in the LysM-Cre/IkkβF/F mice were
only 63.73 ± 0.45 pixels in the white matter of lumbar
spinal cord (Fig. 6c-g). To investigate the mechanisms
underlying the reduced BBB compromise observed in the
LysM-Cre/IkkβF/F mice, we examined the expressions of
Fig. 4 Myeloid-specific ikkβ gene deletion decreases the size of lymphatic organs and regulates transcription factors associated with Th1, Th17,
and Treg cells. a and b The spleen (a) and lymph nodes (b) were dissected from each group (n = 5) at 15–18 days after immunization and
weighted. Bars = 100 mm. c Spinal cords were dissected from each group (n = 5) at 15–18 days after immunization to investigate the degree of
recruitment/infiltration of T cells with real-time RT-PCR. The degree of mRNA expression of CD3 was expressed as mean fold-induction ± SEM. d-i
Total RNA was isolated from the lumbar spinal cords of each group (n = 3) at days 15–18 post-immunization to measure the level of the mRNA
expression of inflammatory mediators with real-time RT-PCR. The mRNA levels of IFN-γ (d), IL-23 (e), IL-17 (f), IL-4 (g), IL-5 (h), and Foxp3 (i) are
presented as the fold induction compared with the levels measured in the normal control mice. Data are represented as mean ± SEM. (ANOVA
test; **p < 0.01 versus WT EAE mice; #p < 0.05 and #p <0.01 versus normal control mice)
Lee et al. Molecular Neurodegeneration  (2016) 11:54 Page 12 of 21genes involved in tight junction formation in the cerebral
endothelial cells such as zona occludens and claudin [52].
Upon EAE induction, the mRNA expression of zona
occludens-1, claudin-3, and claudin-5 decreased in the in-
jured spinal cord of WT mice (Fig. 6h-j), indicating a com-
promise of the tight junction formation after EAE.
However, the decrease in the tight junction components
was significantly ameliorated in the LysM-Cre/IkkβF/F mice.Myeloid-specific ikkβ gene deletion maintains BBB
integrity in the spinal cord during EAE
In addition, we characterized the expression of platelet
endothelial cell adhesion molecule-1 (PECAM-1, CD31)
and fibronectin in astrocytes. These are indicators of
BBB disruption [15, 16, 27]. In EAE-induced WT spinal
cord, immunofluorescence for PECAM-1 (Fig. 7a-l) and
fibronectin (Fig. 7m-x) was elevated around or near the
Table 2 Myeloid-specific ikkβ gene deletion regulates the
percentages of CD4+, CD4+/IFN-γ+, CD4+/IL-17+, and
CD4+/CD25+/Foxp3+ T cells
A





CD4+ 0.52 ± 0.17 0.65 ± 0.21 14.47 ± 1.21## 8.18 ±
0.53**
CD8+ 2.53 ± 1.38 2.89 ± 0.13 3.07 ± 0.74 2.76 ± 0.06
CD4+/IFN-γ+ 2.97 ± 0.04 2.98 ± 0.95 11.33 ± 0.69## 6.34 ±
0.22**
CD4+/IL-17+ 3.84 ± 0.94 3.01 ± 0.12 14.35 ± 1.21## 5.43 ±
0.63**
CD4+/IL-4+ 0.41 ± 0.09 0.49 ± 0.29 0.87 ± 0.13 0.94 ± 0.27




0.46 ± 0.06 0.74 ± 0.10 1.55 ± 0.15## 4.05 ±
0.80*
B





CD4+ 8.43 ± 0.64 8.13 ± 0.84 27.77 ± 2.33## 19.96 ±
2.96*
CD8+ 4.85 ± 0.00 4.39 ± 0.10 4.71 ± 1.08 4.06 ± 0.72
CD4+/IFN-γ+ 1.01 ± 0.09 1.24 ± 0.01 9.40 ± 1.98## 4.59 ±
0.72*
CD4+/IL-17+ 0.13 ± 0.53 0.10 ± 0.34 14.76 ± 2.64## 4.13 ±
0.66**
CD4+/IL-4+ 4.55 ± 0.60 4.29 ± 0.52 3.49 ± 1.32## 4.01 ± 0.94
CD4+/Foxp3+ 16.49 ±
1.02




5.00 ± 0.21 4.96 ± 0.57 2.75 ± 0.01## 4.41 ±
0.13**
Spinal cords (A) and lymph nodes (B) were dissected from each group (n = 5)
at day 15–18 post-immunization to investigate the degree of differentiation
and recruitment/infiltration of CD4+ T cells with flow cytometry. Spot plot
graphs and their legends in details can be found in the Additional file 4. Data
are represented as mean ± SEM. (ANOVA test; * p < 0.05 and **p < 0.01 versus
WT EAE mice; #p < 0.05 and ##p <0.01 versus normal control mice)
Lee et al. Molecular Neurodegeneration  (2016) 11:54 Page 13 of 21activated GFAP-positive astrocytes. Some immunofluor-
escence for PECAM-1 and fibronectin was also detected
in the activated GFAP-positive astrocytes in the white
matter of the spinal cords from the WT mice compared
to those from the normal control group. However, the
increased expressions were clearly decreased, corre-
sponding to the suppression of astrocyte activation in
the LysM-Cre/IkkβF/F EAE mice (Fig. 7d, h, l, p, t, and
x). The levels of PECAM-1 and fibronectin expression in
the lumbar spinal cord measured by Western blot assay
were consistent with the immunohistochemistry data
(Fig. 7y-aa). To further understand the association be-
tween conditional deletion of IKKβ in myeloid cells andimmune-mediated reactions/BBB permeability, we com-
pared the expression of PECAM-1 and Evans blue dye at
a different time points (onset and peak stages) during
EAE (Additional file 5). In EAE-induced WT spinal cord,
immunofluorescence signals for PECAM-1 (Additional
file 5a-i) and Evans blue dye (Additional file 5a-c) were
slightly increased at the onset stage of neurological im-
pairment compared to those in normal control mice.
When the signals were merged with each other, their
intensities were slightly decreased in EAE-induced
LysM-Cre/IkkβF/F spinal cord (Additional file 5a-d and
a-k). However, the immunofluorescence intensities of
PECAM-1 (Additional file 5a-k) and Evans blue dye
(Additional file 5a-e) were clearly increased in the
astrocyte of the spinal cord at the peak stage of neuro-
logical impairment (15–18 days post-immunization) in
EAE-induced WT mice compared to those in normal con-
trol mice. However, these intensities were decreased in
EAE-induced LysM-Cre/IkkβF/F spinal cord (Additional
file 5a-f, l, and r). The results were in agreement with
changed in the level of Iba-1- (Additional file 5b) and
CD68-immunoreactivity (Additional file 5c) in onset and
peak stages of neurological impairment.
Myeloid IKKβ deletion attenuates transferred EAE
To assess the ability of myeloid Ikkβ deletion on trans-
ferred EAE, we performed transferred EAE experiment.
As respected, EAE symptoms of WT and LysM-Cre/
IkkβF/F recipients receiving T cells from LysM-Cre/IkkβF/
F donors were significantly lower than those of WT and
LysM-Cre/IkkβF/F recipients receiving T cells from WT
donors, respectively (Fig. 8a and Table 3). The onsets of
EAE in WT (13.6 ± 1.6 days) and LysM-Cre/IkkβF/F re-
cipients (11.6 ± 1.4 days) receiving T cells from LysM-
Cre/IkkβF/F donors were delayed than that in WT (7.4 ±
1.6 days) and LysM-Cre/IkkβF/F (9.4 ± 0.2 days) recipients
receiving T cells from WT donors, corresponding with
decreased maximal clinical score, sum of clinical score,
and mortality of EAE (Fig. 8a and Table 3). The overall
severity of disease as assessed by cumulative disease
index in recipients receiving T cells from LysM-Cre/
IkkβF/F donors was significantly lower compared to that
in recipients receiving T cells from WT donors (Fig. 8b).
Discussion
In this study, we investigated the in vivo role of IKK/NF-
κB-dependent inflammatory myeloid cell activation in
EAE using LysM-Cre/IkkβF/F mice. We found that inhi-
biting inflammatory myeloid cell activation delayed the
onset day and alleviated the severity of EAE clinical
signs, which was accompanied by reduced demyelination
and immune cell infiltration in the spinal cord. The
beneficial mechanism of myeloid IKKβ deletion was as-
sociated with diminished expansion of Th1 and Th17
Fig. 5 Myeloid-specific ikkβ gene deletion inhibits the mRNA expression of co-stimulatory molecules in macrophages and regulates the proliferation
of T cells by co-culture with microglia. a-b Spleen mononuclear cells obtained from WT and LysM-Cre/IkkβF/F mice at 15–18 days after immunization
were incubated with MOG35–55 peptide and PLP peptide for 48 and 72 h. The cells were pulsed for 18 h with solution containing
3H-methylthymidine
and thymidine incorporation was measured. The results were expressed as counts per minute (mean ± SEM). c-e Macrophages obtained
from WT and LysM-Cre/IkkβF/F mice were stimulated with lipopolysaccharide for 6 h. The mRNA expression levels of CD40 (c), CD80 (d),
and CD86 (e) were determined using real-time RT-PCR. Data are represented as mean ± SEM. (ANOVA test; *p < 0.05 and **p < 0.01 versus
supernatant from WT mice; ##p < 0.01 versus supernatant from normal control mice). f Microglial cells were isolated from brains of
postnatal 1–3 day WT or LysM-Cre/IkkβF/F mice. At 15 days after EAE induction, CD4+ T cells (95 % pure) were harvested from lymph
nodes of each group using anti-mouse CD4 magnetic beads. MOG35–55 peptide-specific T cells were co-cultured with microglia for 24 h
and incubated with APC anti-mouse CD4, PE anti-mouse IFN-γ, FITC anti-mouse IL-17A, PE anti-mouse CD25, and APC anti-mouse Foxp3
antibodies. Far left, CD4+ T cell gate (1 × 104 cells in R2) used to identify CD4+/IFN-γ+, CD4+/IL-17+, and CD4+/CD25+/Foxp3+ T cells.
Representative data and mean ± SEM values from 3 independent experiments are shown in spot plot graphs. (ANOVA test; *p < 0.05 and
**p < 0.01 versus WT microglia and WT T cell group)
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Fig. 6 Myeloid-specific ikkβ gene deletion inhibits BBB permeability in the spinal cord with during EAE. a and b The amount of extravasated
Evans blue dye was quantified in the brain and lumbar spinal cord, at 15–18 days after immunization (n = 5 per group). Representative pictures
(a) and quantitative data (b) are displayed. Blue color in A indicates extravasated Evans blue dye from blood vessels. c-g Representative confocal
images of extravasated Evans blue dye in the lumbar spinal cord from each group (n = 5; c-f) and quantified data (g). Red color in the (c-f)
indicates extravasated Evans blue dye from blood vessels. h-j The mRNA expression levels of junctional proteins [zona occuluden-1 (h), claudin-3
(i), and claudin-5 (j)] in spinal cords from each group were analyzed by real-time RT-PCR. Data are representative of 3 independent experiments
with similar results and the data are expressed as mean fold induction ± SEM. ANOVA test; **p < 0.01 versus supernatant from WT mice; ##p < 0.01
versus supernatant from normal control mice
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Fig. 7 Myeloid-specific ikkβ gene deletion reduces disruption of BBB integrity in the spinal cord during EAE. a-x Spinal cord sections from
WT and LysM-Cre/IkkβF/F EAE mice (n = 5 per group) were double immunostained with anti-PECAM-1 (a-d), fibronectin (m-p), or GFAP (e-h
and q-t) antibodies at 15–18 days after immunization. Bars = 10 μm. y-aa Spinal cords from each group (n = 3 per group) were analyzed
to test the level of protein expression of PECAM-1 (y and z) and fibronectin (y and aa) with Western blot. Data are represented as mean
± SEM. (ANOVA test; **p < 0.01 versus WT EAE mice; ##p < 0.01 versus normal control mice)
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to reduced BBB damage.
In the brain of MS patients or in the EAE animal
model, IKK/NF-κB activation is detected in various cell
types not only in brain-infiltrating immune and inflam-
matory cells but also in neurons and oligodendrocytes
[41]. The critical role of NF-κB signaling pathways in
the development of EAE has long been investigated in
in vitro as well as in vivo studies using conventional
knockout mice [11, 21]. More recently, the cell-type spe-
cific in vivo roles of NF-κB activation in EAE pathologyare currently being characterized by different groups using
cell type-specific conditional knockout or transgenic mice.
For instance, transgenic inactivation of astroglial NF-κB
improved the functional and pathological outcomes of
EAE by decreasing the astrocyte proinflammatory cyto-
kines and chemokines, indicating the detrimental role of
astrocyte NF-κB activation in EAE [3, 4]. Neuronal spe-
cific NF-κB ablation through transgenic expression of an
IkBα super-repressor (IκBɑ-AA) did not influence neuro-
axonal degeneration in EAE, suggesting that neuronal NF-
κB signaling is dispensable for EAE [32].
Fig. 8 Myeloid-specific ikkβ gene deletion reduces transferred EAE. a-b T-cells were isolated from lymph nodes of WT or LysM-Cre/IkkβF/F donor (n = 5
per group) at 15–18 days after induction of active EAE and re-stimulated with MOG35–55 peptide (25 μg/ml). Purified T cells (1 × 107) were transferred
i.v. into sub-lethally irradiated WT or LysM-Cre/IkkβF/F recipient mice. Disease development was monitored daily (a) and cumulative disease index (b)
was assessed. Experimental groups include Wild type→Wild type, Wild type→ LysM-Cre/IkkβF/F, LysM-Cre/IkkβF/F→Wild type, and LysM-Cre/IkkβF/F→
LysM-Cre/IkkβF/F. Data are represented as mean ± SEM. (ANOVA test; *p < 0.05 and **p < 0.01 versus Wild type→Wild type EAE mice)
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NF-κB signaling pathways for autoimmune demyelinating
disease in CNS cells (neurons and astrocytes) is relatively
well-developed, the exact functions of the NF-κB signaling
pathways in myeloid cells for MS/EAE remains elusive. In a
study, over-expression of the triggering receptor expressed
on myeloid cells 2 (TREM2), a NF-κB target gene, in mye-
loid cells ameliorated clinical symptoms and reduced de-
myelination as well as axonal damage in the spinal cord of
EAE mice, suggesting a neuroprotective role of myeloid
NF-κB signaling [56]. In a more recent study, constitutive
activation of NF-κB through myeloid specific IkBα deletion
resulted in a more severe clinical course of EAE, indicating
a detrimental role of myeloid NF-κB activation in EAE de-
velopment [13]. Our study using LysM-Cre/IkkβF/F mice ba-
sically confirmed the previous study by Ellrichmann et al.,
demonstrating that myeloid NF-κB signalling plays adetrimental role in EAE [13]. Furthermore, in our study, we
uncovered the mechanisms underlying these detrimental
effects of myeloid NF-κB activation. We found that myeloid
NF-κB signaling affects the T cell activation profile during
EAE; myeloid IKKβ deletion reduced Th1 and Th17 popu-
lations in the spinal cord and lymph nodes, but enhanced
the activation of Treg cells in EAE mice. An altered Th cell
profile can alleviate demyelination and attenuate the sever-
ity of clinical signs of EAE. Therefore, IKKβ/NF-κB-
dependent myeloid activation may contribute to EAE
pathogenesis by increasing Th1 and Th17 cell responses,
while inhibiting Treg cell responses.
The involvement of NF-κB signaling pathways in en-
cephalitogenic T cell activation has been reported in pre-
vious studies. In NF-κB/p50-deficient mice, myelin-
specific T-cells are unable to differentiate into either
Th1- or Th2-type effector cells in vivo [21]. Mice that
Table 3 Myeloid-specific ikkβ gene deletion ameliorates transferred EAE
Group Incidence (%) Mean day of onset (± SEM) Maximal clinical score (± SEM) Sun of clinical score (± SEM) Mortality (%)
Wild type 5/5 7.4 ± 1.6 4.2 ± 0.7 43.7 ± 10.6 10
→Wild type
Wild type 5/5 9.4 ± 0.2 3.6 ± 0.2 33.7 ± 2.1 0
→LysM-Cre/IkkβF/F
LysM-Cre/IkkβF/F 5/5 13.6 ± 1.6* 0.7 ± 0.1** 7.5 ± 2.1** 0
→Wild type
LysM-Cre/IkkβF/F 5/5 11.6 ± 1.4 1.4 ± 0.2** 12.9 ± 1.8** 0
→LysM-Cre/IkkβF/F
T cells were isolated from lymph nodes of WT or LysM-Cre/IkkβF/F donor 15–18 days after induction of active EAE and re-stimulated with MOG35–55 peptide. Purified
T cells (1 × 107) were transferred i.v. into sub-lethally irradiated WT or LysM-Cre/IkkβF/F recipient mice. (ANOVA test; *p < 0.05 and **p < 0.01 versus
WT→WT group)
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main (NBD) peptides did not demonstrate a shift in im-
mune responses from a Th1 to a Th2 profile and exhibited
reduced encephalitogenicity of myelin-specific T cells [11].
In addition, highly impaired T cell response is observed in
splenocyte cultures from T cell specific IKK2 deficient
mice [19]. These Th cell profile changes in previous stud-
ies were mainly attributed to NF-κB signaling in T cells. In
our study, however, we found for the first time to our
knowledge that myeloid NF-κB signaling affects the en-
cephalitogenic T cell activation profile in EAE.
In addition, we found that myeloid NF-κB signalling
also affects Th17 cell differentiation. Myeloid IKKβ dele-
tion attenuated the mRNA expression of IL-17 and IL-
17α, as well as the population of CD4+/IL-17+ T cells in
spinal cords and lymph nodes from EAE mice. NF-κB
signalling in T cells has been implicated in Th17 cell ac-
tivation in previous studies [5, 50]. However, the effect
of myeloid NF-κB activation on Th17 cell differentiation
has not been reported. Thus far, it is not clear how IKK/
NF-κB-mediated myeloid cell activation affect Th1 and
Th17 activations. In our study, we observed the Th1/
Th17-differentiating effect of myeloid IKK/NF-κB activa-
tion both at the spinal cord and the peripheral lymph
nodes. Thus, the effects more likely occur during T cell
activation in the peripheral lymph node by myeoloid-
derived antigen presenting cells (macrophages and mye-
loid dendritic cells). Indeed, in our study, we found that
the expression of various costimulatory molecules and
proinflammatory cytokines in the lymph node were
down-regulated in the LysM-Cre/IkkβF/F mice, which
might be responsible for the reduced Th1 and Th17 cell
activation. However, it is also possible that altered che-
mokine expression in the IKK-deleted spinal cord micro-
glia and macrophage affected the recruitment of Th1 or
Th17 cells from the circulation, which was not formally
tested in our study. In return, we confirmed that T cells
co-cultured with microglia derived from LysM-Cre/
IkkβF/F mice displayed lower percentages of Th1 andTh17 cells but higher percentage of Treg cells than those
in the control group. Taken together, our findings sug-
gest that myeloid IKKβ can potentiate Th1/Th17 T cell
differentiation in the periphery and activation in the
spinal lesion of EAE mice, which can exacerbate the
clinical severity of EAE.
It is well-known that Treg cells are critical for control-
ling disease severity in autoimmunity [7, 12, 53, 62].
Treg cells develop in response to TGF-β and express
high levels of CTLA-4 and Foxp3 [7, 53, 62]. The critical
role of Treg cells in EAE was demonstrated in a study
showing aggravated EAE pathogenesis upon Treg cell
depletion [24]. We confirmed that myeloid IKKβ dele-
tion significantly up-regulated the number of CD4
+/CD25+/Foxp3+ T cells and the mRNA expression of
TGF-β and Foxp3 in the spinal cord and lymph nodes
after the peak point of EAE clinical signs. Our findings
are in line with recent reports showing that artemisinin
analogue SM934 [36], dexamethasone [8], and electroa-
cupuncture [38] ameliorated EAE by enhancing the ex-
pansion and functions of Treg cells. Of note, the Treg
population in peripheral lymph nodes was decreased
upon EAE induction, although it increased in the spinal
cord. It is likely that the Th1 and Th17 cell proliferation
rate in peripheral lymph nodes outweigh the Treg prolif-
eration rate, thus decreasing the relative Treg percentage
upon EAE induction. Nevertheless, our results suggest
that the EAE-suppressing effects of myeloid IKKβ dele-
tion may be partly due to the increase in the differenti-
ation/activation of Treg cells in the periphery and
recruitment/infiltration into the spinal lesion.
Besides the effects on peripheral T cell activation, our
data suggest that attenuated BBB compromise may be
another mechanism for the EAE-suppressing effects of
myeloid IKK/NF-κB signaling. In our study, the EAE-
induced BBB leakage measured by Evans blue staining
was clearly reduced by myeloid IKKβ deletion, demon-
strating that myeloid IKK/NF-κB activation potentiates
BBB damage. The effects of myeloid IKKβ on BBB
Lee et al. Molecular Neurodegeneration  (2016) 11:54 Page 19 of 21compromise was also confirmed by immunostaining of
PECAM-1 and fibronectin proteins, other markers of
BBB damage, which were increased in the spinal cords
of WT EAE mice in correlation with astrocytic activa-
tion. However, the increased immunofluorescence was
diminished in LysM-Cre/IkkβF/F mice in agreement with
the reduction of astrocytic activation. These data suggest
that the suppression of astrocytic activation by myeloid
IKKβ deletion may be associated with reduced perme-
ability of the BBB. These findings were similar but dis-
tinct from the previous studies in which PECAM-1 and
fibronectin were increased in proportion to the level of
inflammation in EAE and were observed around capil-
laries in the CNS of EAE mice [15, 29, 45, 61]. In our
study, we found that PECAM-1 and fibronectin are up-
regulated in activated astrocytes. Although we have not
elucidated how myeloid NF-κB activation might have in-
duced astrocyte activation and PECAM-1/fibronectin
upregulation, our result suggests putative reciprocal in-
teractions among myeloid cells (specifically, M1/M2
phenotype cells), astrocyte, proinflammatory cytokines/
chemokines, cell adhesion molecule, and endothelial
cells in the spinal cord. Further studies regarding the mo-
lecular interaction of myeloid NF-κB activation and BBB
are merited. Since astrocytes are critical in maintaining
BBB integrity [51, 60], IKK/NF-κB-mediated myeloid acti-
vation might compromise the normal integrity of the BBB
by inducing astrocyte activation. Additionally, although
pertussis toxin is very effective in permeabilizing an intact
BBB [35] and thus allowing myelin-specific T cells to enter
the CNS, other mechanisms by which pertussis toxin pro-
motes neuroinflammation in EAE have been suggested
[58]. Our results suggest that the enhancement effect of
pertussis toxin and inhibitory effect of myeloid IKKβ dele-
tion for permeability of the BBB might be in a mixture in
the present study. The BBB of myeloid IKKβ deleted mice
might be more resistant to pertussis toxin than WT mice,
although the physiologic mechanism remains unclear.
Conclusions
We found that myeloid cell-specific IKKβ expression
plays a pivotal role for demyelination in the EAE
model. The inhibition of NF-κB activation by condi-
tional deletion of IKKβ in myeloid cells resulted in alle-
viated clinical signs of EAE compared with WT mice,
corresponding with decreased spinal demyelination and
glial activation, decreased infiltration of peripheral im-
mune cells, and reduced expression of proinflammatory
mediators. Interestingly, these beneficial effects were asso-
ciated with the suppression of Th1 and Th17 T cells, the
up-regulation of Treg cells, and reduced BBB damage.
Our findings imply that therapies targeting IKKβ function
in myeloid cells may be effective for the treatment of MS
and other demyelinating pathologies of the CNS.Additional files
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anti-mouse IL-4, PE anti-mouse CD25, and APC anti-mouse Foxp3
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and CD4+/CD25+/Foxp3+ T cells. Representative data and mean ± SEM
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LysM-Cre/IkkβF/F EAE mice (n = 5 per group), sectioned, and
immunofluorescent stained with PECAM-1 (A), Iba-1 (B), and CD68 (C)
antibodies. Representative confocal images display extravasated Evans
blue dye (a-f in A, B, and C), PECAM-1 (A.g-l), Iba-1 (B.g-i), and CD68
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